SPOTLIGHT: India to convert sites into drug labs

After shuttering three of its oldest vaccine manufacturing facilities for failing to abide by good manufacturing practices, Indian officials have named an expert panel to convert the plants into drug testing laboratories. In addition to safety and efficacy trials, the labs will also be responsible for identifying counterfeit drugs. Drug regulatory officials from WHO and Canada will be brought in to advise the panel in the best way to structure the new labs. Article

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.